
  
    
      
        
        
        Streptococcus_NNP pneumoniae_NN is_VBZ a_DT common_JJ bacterium_NN that_WDT is_VBZ present_JJ
        in_IN the_DT nasopharynx_NN of_IN many_JJ children_NNS and_CC some_DT adults_NNS ,_, where_WRB it_PRP causes_VBZ no_DT harm_NN to_TO its_PRP$ carrier_NN
        but_CC can_MD be_VB transmitted_VBN to_TO others_NNS ._. If_IN it_PRP moves_VBZ beyond_IN the_DT nasopharynx_NN ,_, however_RB ,_, it_PRP can_MD cause_VB
        ear_NN infections_NNS or_CC invasive_JJ disease_NN ,_, such_JJ as_IN pneumonia_NN or_CC meningitis_NNS ._. Invasive_NNP disease_NN from_IN
        this_DT organism_NN occurs_VBZ especially_RB in_IN children_NNS ,_, the_DT elderly_JJ ,_, and_CC individuals_NNS with_IN weakened_VBN
        immune_JJ systems_NNS ._.
        The_DT protective_JJ effect_NN of_IN antibodies_NNS against_IN bacterial_JJ pneumonia_NN has_VBZ been_VBN appreciated_VBN
        since_IN the_DT 1930_CD s_VBZ ,_, when_WRB it_PRP was_VBD shown_VBN that_DT serum_NN therapy—the_NN transfer_NN of_IN serum_NN from_IN an_DT
        immunized_JJ animal_NN to_TO a_DT patient_NN with_IN acute_JJ disease_NN caused_VBN by_IN the_DT same_JJ bacterial_JJ strain—could_NN
        reduce_VB mortality_NN from_IN pneumococcal_NN pneumonia_NN by_IN half_NN ._. Subsequent_JJ development_NN of_IN vaccines_NNS
        based_VBN on_IN the_DT bacterium_NN 's_POS polysaccharide_NN capsule_NN ,_, which_WDT could_MD protect_VB against_IN infection_NN ,_,
        confirmed_VBD that_IN an_DT endogenous_JJ antibody_NN response_NN can_MD provide_VB protection_NN against_IN invasive_JJ
        disease_NN ._.
        One_CD challenge_NN for_IN vaccine_NN development_NN has_VBZ been_VBN the_DT existence_NN of_IN many_JJ different_JJ serotypes_NNS
        (_( the_DT same_JJ species_NNS of_IN bacteria_NNS but_CC with_IN different_JJ composition_NN of_IN the_DT polysaccharide_NN
        capsule_NN )_) ._. As_IN protection_NN usually_RB does_VBZ n't_RB extend_VB to_TO different_JJ serotypes_NNS ,_, vaccination_NN with_IN
        capsule_NN components_NNS from_IN different_JJ serotypes_NNS is_VBZ necessary_JJ to_TO ensure_VB broad_JJ protection_NN ._. Such_JJ
        vaccines_NNS have_VBP been_VBN shown_VBN to_TO be_VB efficient_JJ and_CC safe_JJ ._. They_PRP are_VBP now_RB recommended_VBN in_IN many_JJ
        countries_NNS for_IN infants_NNS and_CC toddlers_NNS ,_, and_CC for_IN people_NNS over_IN 65_CD —_NN the_DT two_CD age_NN groups_NNS in_IN which_WDT
        invasive_JJ disease_NN is_VBZ most_JJS common—and_NN for_IN others_NNS who_WP are_VBP at_IN increased_VBN risk_NN of_IN pneumococcal_NN
        disease_NN (_( e_SYM ._. g_SYM ._. ,_, patients_NNS with_IN heart_NN ,_, kidney_NN ,_, liver_NN ,_, or_CC lung_NN disease_NN ,_, or_CC who_WP have_VBP had_VBD a_DT
        splenectomy_NN )_) ._.
        Even_RB without_IN vaccination_NN ,_, however_RB ,_, most_RBS exposed_VBN individuals_NNS will_MD never_RB get_VB invasive_JJ
        disease_NN ._. Instead_RB ,_, they_PRP develop_VBP natural_JJ immunity_NN against_IN the_DT different_JJ serotypes_NNS ,_, though_IN
        this_DT immunity_NN gradually_RB declines_VBZ with_IN old_JJ age_NN ._. Marc_NNP Lipsitch_NNP and_CC colleagues_NNS wanted_VBD to_TO
        understand_VB the_DT immunological_JJ basis_NN of_IN this_DT natural_JJ immunity_NN ,_, and_CC specifically_RB whether_IN it_PRP
        was_VBD due_JJ to_TO anticapsular_NN antibodies_NNS ._.
        If_IN protection_NN from_IN invasive_JJ disease_NN is_VBZ due_JJ to_TO acquiring_VBG anticapsular_NN antibodies_NNS against_IN
        each_DT of_IN the_DT pneumococcal_NN serotypes_NNS ,_, they_PRP argued_VBD ,_, this_DT would_MD lead_VB to_TO two_CD predictions_NNS about_IN
        the_DT age_NN distribution_NN of_IN disease_NN caused_VBN by_IN the_DT different_JJ serotypes_NNS in_IN the_DT non-vaccinated_JJ
        population_NN ._. First_LS ,_, for_IN serotypes_NNS that_WDT are_VBP more_RBR common_JJ and_CC therefore_RB encountered_VBD earlier_RBR in_IN
        life_NN ,_, children_NNS should_MD develop_VB immunity_NN more_RBR quickly_RB ,_, causing_VBG disease_NN from_IN these_DT types_NNS to_TO
        drop_VB off_RP earlier_RBR in_IN life_NN than_IN disease_NN from_IN the_DT less_RBR common_JJ types_NNS ._. Second_JJ ,_, protection_NN
        against_IN invasive_JJ disease_NN from_IN a_DT particular_JJ serotype_NN should_MD coincide_VB with_IN the_DT acquisition_NN of_IN
        antibodies_NNS against_IN that_DT serotype_NN ,_, on_IN both_DT the_DT individual_NN and_CC population_NN level_NN ._.
        Neither_DT prediction_NN was_VBD borne_VBN out_IN by_IN the_DT actual_JJ data_NN the_DT researchers_NNS analyzed_VBD ,_, suggesting_VBG
        that_IN there_EX is_VBZ more_JJR to_TO natural_JJ immunity_NN against_IN pneumococcal_NN disease_NN than_IN just_RB anticapsular_NN
        antibodies_NNS ._. The_DT study_NN does_VBZ n't_RB demonstrate_VB what_WP the_DT additional_JJ components_NNS are_VBP ,_, but_CC
        additional_JJ research_NN might_MD not_RB just_RB teach_VB us_PRP about_IN our_PRP$ immune_JJ system_NN but_CC also_RB provide_VB clues_NNS
        for_IN further_JJ vaccine_NN development_NN ._. As_IN the_DT authors_NNS say_VBP ,_, “ A_DT better_JJR understanding_NN of_IN the_DT
        mechanisms_NNS that_WDT underlie_VB natural_JJ immunity_NN to_TO pneumococcus_JJ could_MD pave_VB the_DT way_NN for_IN the_DT
        development_NN of_IN more_JJR effective_JJ ,_, species-specific_JJ pneumococcal_NN vaccines_NNS ._.”
      
    
  
